Nordic Biotech is a specialized biotech venture capital fund focusing primarily on Nordic Countries but also rest of EU. The investment focus is mainly early stage, but also spin-outs and restructurings. Nordic Biotech is advised by NB Capital, an advisory firm focused on investing capital in public and private equity markets using principles of risk aversion. The team behind NB Capital has extensive experience in biotech investment and has co-founded or invested in a series of biotech successes, such as Genmab A/S, Profound Pharma A/S, Biomarin Inc., Zealand Pharma A/S and many others over the last decade. NB Capital is affiliated with a strong advisory board consisting of worldwide based pharmaceutical research and development executives. NB Capital has a high-class investor base, amongst them: H. Lundbeck A/S, Danish Growth Fund, Biotechnology Value Fund L.P., The European Investment Fund, HBM Bioventures and Wallenberg Capital.
Rosetta Capital, formerly BioScience Managers, is based in the United Kingdom and has a multinational team from the venture capital, pharmaceutical and biotechnology sectors. Since its founding in 2001, Rosetta has been working with entrepreneurs and life science companies to help them achieve their ambitions. The Rosetta team engages strategically with portfolio company boards, management teams and co-investors to secure successful IPOs and trade sales, including the sale of Enobia to Alexion for $1.1 billion and Cytochroma to Opko for $300M. Rosetta’s investors are comprised of leading international institutional investors and Rosetta has more than 30 active portfolio companies across Europe, North America and Asia.
BVF Partners L.P.
BVF Partners L.P. is a San Fransisco-based private investment firm which invests exclusively in biotechnology companies.